STOCK TITAN
  1. Home
  2. News
  3. JSPR

Jasper Therapeutics (JSPR) Stock News

JSPR Nasdaq

Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.

Jasper Therapeutics develops briquilimab, a clinical-stage antibody therapy targeting KIT (CD117) for mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria and asthma. Company news centers on briquilimab clinical data from BEACON, open-label extension and ETESIAN studies, financial results and corporate updates, investor conference participation, financing activity and governance changes tied to its development strategy.

News

Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.11%
Tags
none
-
News

Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
clinical trial
-
News

Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
clinical trial
News

Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.08%
Tags
earnings
-
News

Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.08%
Tags
conferences
-
News

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
clinical trial
News

Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
management
-
News

Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.25%
Tags
conferences
-
News

Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.25%
Tags
clinical trial
News

Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.97%
Tags
management

FAQ

What is the current stock price of Jasper Therapeutics (JSPR)?

The current stock price of Jasper Therapeutics (JSPR) is $0.7224 as of August 24, 2026.

What is the market cap of Jasper Therapeutics (JSPR)?

The market cap of Jasper Therapeutics (JSPR) is approximately 24.0M.